Business

How Regulatory Readiness Shapes Pharmaceutical Risk Management

Updated

Pharmaceutical companies operate in an environment where regulatory compliance, product quality, and operational efficiency directly influence business performance. From clinical development to commercialisation, each stage requires strict documentation, data integrity, and quality assurance.

Failing to meet these expectations can cause delays, added costs, reputational damage, and setbacks in product development. According to Pharma Manufacturing, 150 of the 202 FDA Complete Response Letters (CRLs) issued between 2020 and 2024 involved quality or manufacturing issues. They represented 74% of the total application rejections.

These issues included manufacturing process deficiencies, problems identified during facility inspections, and chemistry, manufacturing, and controls (CMC) concerns.

Join The European Business Briefing

New subscribers this quarter are entered into a draw to win a Rolex Submariner. Join 40,000+ founders, investors and executives who read EBM every day.

Subscribe

Regulatory readiness helps companies identify potential compliance issues before they develop into larger problems. It also gives management teams a clearer understanding of operational weaknesses, resource requirements, and cross-departmental responsibilities.

Understanding the Connection Between Regulatory Readiness and Risk Management

Regulatory readiness refers to a company’s ability to demonstrate that its processes, records, and quality systems meet applicable regulatory requirements. It involves maintaining accurate documentation, conducting internal reviews, monitoring compliance, and ensuring employees understand their responsibilities.

Instead of treating preparation as a task that begins shortly before an inspection, pharmaceutical companies can build it into everyday operations. Consider the shortcomings affecting quality risk management (QRM) in the pharmaceutical industry.

There are four major challenges:

  • Subjective risk assessments
  • Inadequate management of supply chain and product availability risks
  • Confusion about the appropriate level of formality in risk evaluations
  • Unclear risk-based decision-making processes

Effective QRM requires pharmaceutical companies to integrate risk management with knowledge management. They should also use evidence-based assessments, strengthen change control procedures, and establish early warning systems to identify potential quality and supply issues.

“Sometimes we still really need to understand the benefit of proactive risk management so that teams work in a continual improvement environment that allows for a robust PQS [pharmaceutical quality system],” says Alice Redmond, Chief Strategy Officer at Commissioning Agents, Inc. (CAI)

Regulatory readiness supports this process by helping companies identify weaknesses before they affect clinical studies, manufacturing activities, or product approvals.

How Documentation Quality Affects Regulatory Risk

Accurate documentation provides evidence that pharmaceutical activities have been conducted according to established procedures and applicable requirements. Clinical trial records, manufacturing logs, quality reports, and training documents help demonstrate accountability throughout the product lifecycle.

The European Commission launched a stakeholder consultation in July 2025 to revise EudraLex Volume 4 Good Manufacturing Practice (GMP) guidelines. One focus area was revising Chapter 4 (Documentation). The updated Chapter 4 emphasises risk-based documentation management, data governance, and the accuracy, integrity, accessibility, and readability of records throughout their lifecycle.

Maintaining consistency across these sources requires clear ownership, standardised processes, and regular quality checks, which pharmaceutical companies support with a Trial Master File (TMF). But as Just In Time GCP suggests, a TMF should not be only for storing documents. It should be designed for inspection readiness.

A TMF inspection can help assess whether a clinical trial’s essential records are complete, consistent, and readily accessible for regulatory review. Preparing for this process also encourages teams to identify documentation gaps, resolve discrepancies, and maintain appropriate oversight of trial records.

These practices can reduce the likelihood of avoidable findings during regulatory assessments.

What is the difference between a source document and an essential clinical trial document?

A source document contains original information or records observations made during a clinical trial, such as laboratory results or clinical notes. Essential clinical trial documents show that the study was conducted in accordance with applicable requirements and established procedures. Some source documents may also qualify as essential documents, depending on their purpose and the applicable regulatory framework.

Building a Proactive Approach to Compliance Monitoring

Pharmaceutical companies can strengthen their risk management strategies by monitoring compliance regularly rather than relying solely on periodic external assessments. Internal audits, quality reviews, and documented follow-up procedures help identify problems while there is still time to address them.

This approach also allows organisations to evaluate whether existing controls remain effective as projects, regulations, and business priorities change.

A structured monitoring programme should define the areas to review, the assessment frequency, and the employees responsible for corrective actions. Risk-based prioritisation helps teams focus on activities with greater potential consequences, such as data integrity, patient safety, product quality, and critical documentation requirements.

The proposed changes to EudraLex Volume 4 Good Manufacturing Practice (GMP) guidelines focus on these areas. They emphasise evidence-based risk assessments, scientific justification, proportional risk management, and stronger knowledge management throughout a product’s lifecycle. They also encourage pharmaceutical manufacturers to identify production risks early, address supply chain vulnerabilities, and prevent medicine shortages.

The Role of Digital Systems in Regulatory Risk Management

Digital tools can improve the consistency, accessibility, and traceability of information across pharmaceutical operations.

Electronic document management platforms, quality management systems, and clinical trial management technologies can help teams organise records, monitor workflows, and maintain visibility into outstanding tasks. Automated notifications and review logs may also reduce the likelihood that teams overlook important actions.

However, adopting new technology does not automatically eliminate compliance risks. Therefore, governments and agencies usually approach this with a standard framework.

The European Medicines Agency (EMA) published a report detailing how it incorporated stakeholder feedback into its draft reflection paper on the use of artificial intelligence (AI).

The revisions clarified technical terminology, expanded the glossary, broadened the paper’s scope to include simpler machine learning technologies, and refined risk classifications. The document also clarifies data availability, the use of third-party AI systems, and prospective testing of machine learning models.

Poor system configuration, unclear access permissions, inconsistent data entry, and inadequate employee training can create additional problems. Companies need to establish appropriate governance policies and, where required by applicable regulations, validate computerised systems.

What should pharmaceutical companies consider when selecting a document management system?

Companies should assess the system’s audit trail capabilities, access controls, version management, search functionality, integration options, and support for applicable regulatory requirements. They should also evaluate vendor reliability, implementation costs, data migration needs, and employee training requirements. A system that fits existing workflows and offers appropriate security controls can support more consistent document management.

Managing the Financial and Operational Consequences of Noncompliance

Regulatory failures can affect pharmaceutical businesses through several channels. Additional investigations, corrective actions, delayed approvals, and repeated documentation reviews can increase operating expenses. In serious cases, compliance problems may interrupt clinical development, disrupt manufacturing schedules, or delay a product’s commercial availability.

For instance, 210 Good Manufacturing Practice (GMP) inspections were requested for centrally authorised medicines in 2024. Similarly, European Economic Area authorities issued 10 GMP non-compliance statements. This restricted the sale of medicines manufactured at the affected sites in the EU.

The EMA also reported a 24% increase in Good Clinical Practice (GCP) inspections compared with 2023 and coordinated 18 pharmacovigilance inspections. Additionally, the Agency received 395 suspected quality defect notifications, 221 of which were confirmed and resulted in batch recalls.

These consequences make regulatory readiness both a business planning concern and a quality responsibility. Management teams can evaluate compliance-related risks alongside budget forecasts, project schedules, vendor performance, and resource allocation decisions. This broader view helps organisations account for the time and staffing required to maintain appropriate controls.

How should pharmaceutical companies prioritise compliance investments when budgets are limited?

Management should prioritise investments according to potential patient safety implications, regulatory exposure, business continuity concerns, and the likelihood of failure. Existing audit findings and recurring quality issues can help identify areas requiring immediate attention. Companies should also consider whether a proposed investment addresses the root cause and delivers measurable benefits over time.

Key Statistics on Pharmaceutical Compliance and Regulatory Risk

FDA Complete Response Letters (2020–2024) 150 of 202 involved quality or manufacturing issues (74%)
EU GMP inspections in 2024 210 inspections requested for centrally authorised medicines
GMP non-compliance statements 10 issued by European Economic Area authorities
GCP inspections Increased 24% compared with 2023
Pharmacovigilance inspections 18 coordinated by the EMA
Suspected quality defect notifications 395 received by the EMA
Confirmed quality defects 221 cases resulted in batch recalls
EudraLex Volume 4 revision Stakeholder consultation launched in July 2025

Regulatory readiness helps pharmaceutical companies identify weaknesses, maintain reliable documentation, and reduce the likelihood of compliance failures. Its value extends beyond preparation for external reviews, supporting better operational planning, stronger accountability, and more effective use of business resources.

Companies that integrate compliance monitoring, digital governance, and structured risk assessments into their everyday processes can respond to regulatory expectations with greater confidence. A proactive approach also helps management teams recognise recurring problems and address their underlying causes.

Nick Staunton

Nick Staunton is the Editor and Chief Executive of European Business Magazine, one of Europe's leading business and geopolitical analysis publications. He writes primarily on European markets, fintech, defence industry consolidation, and the business impact of geopolitical events. Nick has over a decade of experience in digital publishing and holds editorial responsibility for EBM's coverage of European rearmament, the Iran war's economic consequences, and the structural shifts reshaping European capital markets. He is based in the United Kingdom and is also Chief Executive of NST Publishing Ltd, the parent company of European Business Magazine

Leave a Reply

Your email address will not be published. Required fields are marked *